Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, R. Delva et al.|Journal of Clinical Oncology|2011Cited by 9